Eli Lilly is testing several antibodies in its efforts against COVID-19 but says a monotherapy, if successful, would help optimize manufacturing. Eli Lilly has several potential therapies in the clinic attempting to take on COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. But speaking during the firm’s second quarter financial call last week, chief scientific officer Dan Skovronsky said the two programs he is most excited about are virus neutralizing antibodies for the treatment and prevention of COVID-19 are…